QUEBEC, December 19, 2025 — Leads & Copy —
Devonian Health Group Inc. (TSXV: GSD) (OTCQB: DVHGF) has announced the grant of stock options to its directors, employees, and a consultant. The biopharmaceutical company specializes in developing prescription drugs for inflammatory diseases.
The Board of Directors approved the granting of 2,948,056 stock options, with 2,798,056 options granted to directors. These options are exercisable at a price of $0.18 on the grant date and will remain valid for 10 years.
Additionally, the Board approved 385,950 stock options for company employees as part of their performance bonus and as retainer. A research and development consultant received 100,000 stock options. These options vest according to the following schedule: 25% on the grant date, followed by 25% per year for the subsequent three years.
Devonian’s lead product, Thykamine™, derived from the SUPREX™ platform, targets inflammation and oxidative stress-related health conditions. These include ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. The anti-inflammatory, anti-oxidative, and immunomodulatory properties of Thykamine™ have been demonstrated through in vitro and in vivo studies, a Phase IIa clinical study in patients with mild-to-moderate distal ulcerative colitis, and a Phase II study in adult patients with mild-to-moderate Atopic Dermatitis. Patents cover both Thykamine™ and the SUPREX™ platform in several North American, European, and Asian countries.
Devonian Health Group Inc. is focused on developing drugs for autoimmune inflammatory conditions. The company leverages over 15 years of research and is supported by U.S. Food and Drug Administration regulatory guidelines that favor an efficient drug development pathway for prescription botanical drug products.
Devonian also develops cosmeceutical products and owns a commercialization subsidiary, Altius, which sells prescription pharmaceutical products in Canada under license from brand-name pharmaceutical companies.
Incorporated in 2015 and headquartered in Quebec, Canada, Devonian operates a state-of-the-art extraction facility. Devonian is publicly traded on the TSX Venture Exchange (TSXV: GSD) and on the OTCQB Venture Market (OTCQB: DVHGF).
For more information, visit www.groupedevonian.com.
Source: Devonian Health Group Inc.
